Abstract：
UNASSIGNED: The identification of biomarkers for different dementias in plasma and cerebrospinal fluid (CSF) has made substantial progress. However, they are observational studies, and there remains a lack of research on dementias with low incidence rates.
UNASSIGNED: We performed a comprehensive Mendelian randomization to identify potential biomarkers for different dementia type.
UNASSIGNED: The summary-level datasets encompassed 734 plasma and 154 cerebrospinal fluid proteins sourced from recently published genome-wide association studies (GWAS). Summary statistics for different dementias, including any dementia (refering to any type of dementia symptoms, 218,792 samples), Alzheimer\'s disease (AD, 63,926 samples), vascular dementia (212,389 samples), frontotemporal dementia (3,024 samples), dementia with Lewy bodies (DLB, 6,618 samples), and dementia in Parkinson\'s disease (216,895 samples), were collected from large GWAS. The primary method is inverse variance weighting, with additional sensitivity analyses conducted to ensure the robustness of the findings.
UNASSIGNED: The molecules released into CSF, namely APOE2 for any dementia, APOE2 and Siglec-3 for AD, APOE2 for vascular dementia, and APOE2 for DLB, might be potential biomarkers. CD33 for AD and SNCA for DLB in plasma could be promising biomarkers.
UNASSIGNED: This is the first study to integrate plasma and CSF proteins to identify potential biomarkers for different dementias.
UNASSIGNED: We performed a comprehensive Mendelian randomization to identify potential biomarkers for different dementia type.
UNASSIGNED: The summary-level datasets encompassed 734 plasma and 154 cerebrospinal fluid proteins sourced from recently published genome-wide association studies (GWAS). Summary statistics for different dementias, including any dementia (refering to any type of dementia symptoms, 218,792 samples), Alzheimer\'s disease (AD, 63,926 samples), vascular dementia (212,389 samples), frontotemporal dementia (3,024 samples), dementia with Lewy bodies (DLB, 6,618 samples), and dementia in Parkinson\'s disease (216,895 samples), were collected from large GWAS. The primary method is inverse variance weighting, with additional sensitivity analyses conducted to ensure the robustness of the findings.
UNASSIGNED: The molecules released into CSF, namely APOE2 for any dementia, APOE2 and Siglec-3 for AD, APOE2 for vascular dementia, and APOE2 for DLB, might be potential biomarkers. CD33 for AD and SNCA for DLB in plasma could be promising biomarkers.
UNASSIGNED: This is the first study to integrate plasma and CSF proteins to identify potential biomarkers for different dementias.
摘要：
■血浆和脑脊液（CSF）中不同痴呆的生物标志物的鉴定取得了实质性进展。然而,它们是观察性研究，并且仍然缺乏对发病率低的痴呆的研究。
■我们进行了全面的孟德尔随机化，以确定不同类型痴呆的潜在生物标志物。
摘要级数据集包括734种血浆和154种脑脊液蛋白，这些蛋白来自最近发表的全基因组关联研究（GWAS）。不同痴呆症的汇总统计数据，包括任何痴呆症（指任何类型的痴呆症症状，218,792个样本)，阿尔茨海默病（AD，63,926个样本)，血管性痴呆（212,389个样本），额颞叶痴呆（3,024个样本），路易体痴呆（DLB，6,618个样本），帕金森病和痴呆症(216,895个样本)，是从大型GWAS中收集的。主要方法是方差倒数加权，进行额外的敏感性分析，以确保结果的稳健性。
■释放到CSF中的分子，即任何痴呆症的APOE2，APOE2和Siglec-3用于AD，APOE2用于血管性痴呆，和APOE2用于DLB，可能是潜在的生物标志物。血浆中用于AD的CD33和用于DLB的SNCA可能是有希望的生物标志物。
■这是整合血浆和CSF蛋白以鉴定不同痴呆的潜在生物标志物的第一项研究。
■我们进行了全面的孟德尔随机化，以确定不同类型痴呆的潜在生物标志物。
摘要级数据集包括734种血浆和154种脑脊液蛋白，这些蛋白来自最近发表的全基因组关联研究（GWAS）。不同痴呆症的汇总统计数据，包括任何痴呆症（指任何类型的痴呆症症状，218,792个样本)，阿尔茨海默病（AD，63,926个样本)，血管性痴呆（212,389个样本），额颞叶痴呆（3,024个样本），路易体痴呆（DLB，6,618个样本），帕金森病和痴呆症(216,895个样本)，是从大型GWAS中收集的。主要方法是方差倒数加权，进行额外的敏感性分析，以确保结果的稳健性。
■释放到CSF中的分子，即任何痴呆症的APOE2，APOE2和Siglec-3用于AD，APOE2用于血管性痴呆，和APOE2用于DLB，可能是潜在的生物标志物。血浆中用于AD的CD33和用于DLB的SNCA可能是有希望的生物标志物。
■这是整合血浆和CSF蛋白以鉴定不同痴呆的潜在生物标志物的第一项研究。
